Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
Right ventricular (RV) failure occurs in an estimated 5-41% of cases involving left
ventricular assist device (LVAD) implantation and has been shown to adversely affect
peri-operative morbidity and mortality. Current therapies to improve RV dysfunction pre and
post-operatively are limited. Inhaled milrinone has been shown in several small human studies
to be safely tolerated and provide favorable effects on pulmonary hemodynamics.
Study Hypothesis: Delivery of inhaled milrinone, a phosphodiesterase III inhibitor, may
provide pulmonary artery vasodilation and therefore improved RV function in patients with end
stage heart failure receiving HeartMate II LVAD as a bridge to cardiac transplantation or as
destination therapy.
Specifically, we aim to:
- demonstrate safety of inhaled milrinone in this patient cohort
- demonstrate efficacy of inhaled milrinone in this patient cohort